Cargando…

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study

OBJECTIVES: To evaluate retention, efficacy, and safety of subcutaneous (SC) abatacept over 2 years in patients with moderate-to-severe RA in the Abatacept SubCutaneOus in Routine clinical practicE (ASCORE) study. METHODS: Patients with RA who initiated SC abatacept 125 mg once weekly were enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Alten, Rieke, Mariette, Xavier, Flipo, René-Marc, Caporali, Roberto, Buch, Maya H., Patel, Yusuf, Marsal, Sara, Sanmartí, Raimon, Nurmohamed, Michael T., Griffiths, Hedley, Peichl, Peter, Bannert, Bettina, Chartier, Melanie, Connolly, Sean E., Lozenski, Karissa, Rauch, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287226/
https://www.ncbi.nlm.nih.gov/pubmed/35536413
http://dx.doi.org/10.1007/s10067-022-06176-1
_version_ 1784748205936738304
author Alten, Rieke
Mariette, Xavier
Flipo, René-Marc
Caporali, Roberto
Buch, Maya H.
Patel, Yusuf
Marsal, Sara
Sanmartí, Raimon
Nurmohamed, Michael T.
Griffiths, Hedley
Peichl, Peter
Bannert, Bettina
Chartier, Melanie
Connolly, Sean E.
Lozenski, Karissa
Rauch, Christiane
author_facet Alten, Rieke
Mariette, Xavier
Flipo, René-Marc
Caporali, Roberto
Buch, Maya H.
Patel, Yusuf
Marsal, Sara
Sanmartí, Raimon
Nurmohamed, Michael T.
Griffiths, Hedley
Peichl, Peter
Bannert, Bettina
Chartier, Melanie
Connolly, Sean E.
Lozenski, Karissa
Rauch, Christiane
author_sort Alten, Rieke
collection PubMed
description OBJECTIVES: To evaluate retention, efficacy, and safety of subcutaneous (SC) abatacept over 2 years in patients with moderate-to-severe RA in the Abatacept SubCutaneOus in Routine clinical practicE (ASCORE) study. METHODS: Patients with RA who initiated SC abatacept 125 mg once weekly were enrolled in the international, observational, prospective multicentre ASCORE study into biologic-naïve or ≥ 1 prior biologic failure cohorts. Primary endpoint: abatacept retention rate at 2 years. Secondary endpoints: proportion of patients with good/moderate EULAR response rates based on DAS28 (ESR), low disease activity and/or remission according to DAS28 (ESR; ≤ 3.2/ < 2.6), SDAI (≤ 11/ ≤ 3.3), CDAI (≤ 10/ ≤ 2.8), and Boolean criteria. Retention rate by baseline serostatus was evaluated post hoc. RESULTS: Overall, 47% of patients remained on abatacept for 2 years, irrespective of treatment line. Higher abatacept retention rates were associated with lower prior biologic exposure. Generally, clinical outcomes showed that the proportion of patients with low disease activity/remission was higher in biologic-naïve patients (vs biologic-failure) and similar in those with 1 and ≥ 2 prior biologic failures. In patients on treatment at 2 years, good/moderate EULAR response rates of ~ 80% were consistently noted irrespective of prior biologic exposure. Across treatment lines, retention was greater in patients with seropositive (vs seronegative) RA. Patients with rheumatoid factor/anti-citrullinated protein antibody single-positive RA who were bio-naïve had higher retention than patients who were bio-experienced. CONCLUSIONS: In the ASCORE study, SC abatacept retention was 47% at 2 years with good clinical outcomes and was well-tolerated in the real-world setting. Abatacept retention and clinical response rates were higher in patients who received abatacept as an earlier- versus later-line biologic drug treatment and in those with seropositive RA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02090556. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10067-022-06176-1.
format Online
Article
Text
id pubmed-9287226
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92872262022-07-17 Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study Alten, Rieke Mariette, Xavier Flipo, René-Marc Caporali, Roberto Buch, Maya H. Patel, Yusuf Marsal, Sara Sanmartí, Raimon Nurmohamed, Michael T. Griffiths, Hedley Peichl, Peter Bannert, Bettina Chartier, Melanie Connolly, Sean E. Lozenski, Karissa Rauch, Christiane Clin Rheumatol Original Article OBJECTIVES: To evaluate retention, efficacy, and safety of subcutaneous (SC) abatacept over 2 years in patients with moderate-to-severe RA in the Abatacept SubCutaneOus in Routine clinical practicE (ASCORE) study. METHODS: Patients with RA who initiated SC abatacept 125 mg once weekly were enrolled in the international, observational, prospective multicentre ASCORE study into biologic-naïve or ≥ 1 prior biologic failure cohorts. Primary endpoint: abatacept retention rate at 2 years. Secondary endpoints: proportion of patients with good/moderate EULAR response rates based on DAS28 (ESR), low disease activity and/or remission according to DAS28 (ESR; ≤ 3.2/ < 2.6), SDAI (≤ 11/ ≤ 3.3), CDAI (≤ 10/ ≤ 2.8), and Boolean criteria. Retention rate by baseline serostatus was evaluated post hoc. RESULTS: Overall, 47% of patients remained on abatacept for 2 years, irrespective of treatment line. Higher abatacept retention rates were associated with lower prior biologic exposure. Generally, clinical outcomes showed that the proportion of patients with low disease activity/remission was higher in biologic-naïve patients (vs biologic-failure) and similar in those with 1 and ≥ 2 prior biologic failures. In patients on treatment at 2 years, good/moderate EULAR response rates of ~ 80% were consistently noted irrespective of prior biologic exposure. Across treatment lines, retention was greater in patients with seropositive (vs seronegative) RA. Patients with rheumatoid factor/anti-citrullinated protein antibody single-positive RA who were bio-naïve had higher retention than patients who were bio-experienced. CONCLUSIONS: In the ASCORE study, SC abatacept retention was 47% at 2 years with good clinical outcomes and was well-tolerated in the real-world setting. Abatacept retention and clinical response rates were higher in patients who received abatacept as an earlier- versus later-line biologic drug treatment and in those with seropositive RA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02090556. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10067-022-06176-1. Springer International Publishing 2022-05-10 2022 /pmc/articles/PMC9287226/ /pubmed/35536413 http://dx.doi.org/10.1007/s10067-022-06176-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Alten, Rieke
Mariette, Xavier
Flipo, René-Marc
Caporali, Roberto
Buch, Maya H.
Patel, Yusuf
Marsal, Sara
Sanmartí, Raimon
Nurmohamed, Michael T.
Griffiths, Hedley
Peichl, Peter
Bannert, Bettina
Chartier, Melanie
Connolly, Sean E.
Lozenski, Karissa
Rauch, Christiane
Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
title Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
title_full Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
title_fullStr Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
title_full_unstemmed Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
title_short Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
title_sort retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ascore study: an international 2-year observational study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287226/
https://www.ncbi.nlm.nih.gov/pubmed/35536413
http://dx.doi.org/10.1007/s10067-022-06176-1
work_keys_str_mv AT altenrieke retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT mariettexavier retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT fliporenemarc retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT caporaliroberto retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT buchmayah retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT patelyusuf retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT marsalsara retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT sanmartiraimon retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT nurmohamedmichaelt retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT griffithshedley retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT peichlpeter retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT bannertbettina retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT chartiermelanie retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT connollyseane retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT lozenskikarissa retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy
AT rauchchristiane retentionofsubcutaneousabataceptforthetreatmentofrheumatoidarthritisrealworldresultsfromtheascorestudyaninternational2yearobservationalstudy